All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityFollow-ons and Rights issues

Cellectis US cap raise closes historic year for biopharma


Cellectis, the French gene-editing company, has launched a $100m US capital raising to help fund its research and development operations. The sector has had a record year for issuance in 2020, as the Covid-19 pandemic has concentrated minds on global healthcare innovation.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login